Last reviewed · How we verify
Mg Cl
Magnesium chloride is an electrolyte replacement that restores depleted magnesium levels in the body.
Magnesium chloride is an electrolyte replacement that restores intracellular and extracellular magnesium levels. Used for Magnesium deficiency (hypomagnesemia), Hypomagnesemia secondary to diuretic use or gastrointestinal loss.
At a glance
| Generic name | Mg Cl |
|---|---|
| Sponsor | University of Vermont |
| Drug class | Electrolyte supplement / mineral replacement |
| Modality | Small molecule |
| Therapeutic area | Electrolyte/Mineral Supplementation |
| Phase | FDA-approved |
Mechanism of action
Magnesium is an essential cofactor for numerous enzymatic reactions and is critical for neuromuscular function, cardiac rhythm, and protein synthesis. Magnesium chloride provides bioavailable magnesium ions to correct deficiency states. It is commonly used as a supplement or therapeutic agent to treat hypomagnesemia and related conditions.
Approved indications
- Magnesium deficiency (hypomagnesemia)
- Magnesium supplementation
Common side effects
- Diarrhea
- Nausea
- Abdominal cramping
Key clinical trials
- Effect of Lidocaine Infusion Versus Dexmedemidine Infusion on the Neurocognitive Function of Elderly Patients Undergoing Endoscopic Retrograde Cholangiopancreatography(ERCP): a Randomized, Controlled Trial. (NA)
- Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma (PHASE2)
- Phase II Trial of Neoadjuvant Chemotherapy (NAC) Alone or in Combination With Immunotherapy Vaccine PRGN-2009 in Subjects With Newly Diagnosed HPV-Associated Oropharyngeal (Head and Neck) Cancer (PHASE2)
- Pulse Glucocorticoid Therapy in Patients With ST-Segment Elevation Myocardial Infarction (PHASE2)
- Individual Response to Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Treatment of Peritoneal Carcinomatosis From Peritoneal Mesothelioma or Atypical Mesothelial Proliferation or From Ovarian, Colorectal, or Appendiceal Histologies (PHASE1)
- MP0317 in Combination With Chemoimmunotherapy in First Line Treatment for Patients With Advanced Biliary Tract Carcinoma (PHASE2)
- A Study to Evaluate the Bioavailability of Pembrolizumab (MK-3475) Via Subcutaneous (SC) Injection of Pembrolizumab Formulated With Berahyaluronidase Alfa (MK-5180) [MK-3475A] In Advanced Solid Tumors (MK-3475A-C18) (PHASE1)
- Romidepsin, Gemcitabine, Dexamethasone and Cisplatin in the Treatment of Peripheral T-Cell and Diffuse Large B-Cell Lymphoma (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Mg Cl CI brief — competitive landscape report
- Mg Cl updates RSS · CI watch RSS
- University of Vermont portfolio CI